Saldanha said he hasn’t yet fully figured out how to deploy much of the proceeds of the licensing deal, but added that he ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

Shares of Glenmark Pharma declined by 2.12% to trade at Rs 2,172.10 in Tuesday's session. The stock is among the top losers on Nifty Midcap 150. At 10:02 am, the stock price reflected a notable ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

An analyst from Anand Rathi said that BHEL is encountering strong resistance in the Rs 265–270 zone, which coincides with its ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...